Dopamine receptor D2 on CD4+ T cells is protective against neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease
- PMID: 34403737
- DOI: 10.1016/j.bbi.2021.08.220
Dopamine receptor D2 on CD4+ T cells is protective against neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease
Abstract
Parkinson's disease (PD) is a chronic neurodegenerative disease. Recently, neuroinflammation driven by CD4+ T cells has been involved in PD pathophysiology. Human and murine lymphocytes express all the five subtypes of dopamine receptors (DRs), DRD1 to DRD5. However, roles of DRs particularly DRD2 expressed on CD4+ T cells in PD remain elucidated. Global Drd1- or Drd2-knockout (Drd1-/- or Drd2-/-) mice or CD4+ T cell-specific Drd2-knockout (Drd2fl/fl/CD4Cre) mice were intraperitoneally injected with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to induce PD with the different mutants. On the 7th day following MPTP injection, mice were assessed for dopaminergic neurodegeneration, locomotor impairments, microglial activation, as well as CD4+ T-cell differentiation and function. Furthermore, in vitro CD4+ T cells were exposed to DRD2 agonist and antagonist and then differentiation and function of the cells were determined. MPTP induced dopaminergic neuronal loss in the nigrostriatal system, motor coordinative and behavioral impairments, microglial activation, and CD4+ T-cell polarization to pro-inflammatory T-helper (Th)1 and Th17 phenotypes. Importantly, either Drd2-/- or Drd2fl/fl/CD4Cre mice manifested more severe dopaminergic neurodegeneration, motor deficits, microglial activation, and CD4+ T-cell bias towards Th1 and Th17 phenotypes in response to MPTP, but Drd1-/- did not further alter MPTP intoxication. DRD2 agonist sumanirole inhibited shift of CD4+ T cells obtained from MPTP-intoxicated mice to Th1 and Th17 phenotypes and DRD2 antagonist L-741,626 reversed sumanirole effects. These findings suggest that DRD2 expressed on CD4+ T cells is protective against neuroinflammation and neurodegeneration in PD. Thus, developing a therapeutic strategy of stimulating DRD2 may be promising for mitigation of PD.
Keywords: CD4(+) T cells; Dopamine receptor D2; Drd2(fl/fl)/CD4(Cre) mice; Neurodegeneration; Neuroinflammation; Parkinson's disease.
Copyright © 2021 Elsevier Inc. All rights reserved.
Similar articles
-
Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease.J Immunol. 2013 May 15;190(10):5048-56. doi: 10.4049/jimmunol.1203121. Epub 2013 Apr 15. J Immunol. 2013. PMID: 23589621
-
Dopamine D2 receptor on CD4+ T cells is protective against inflammatory responses and signs in a mouse model of rheumatoid arthritis.Arthritis Res Ther. 2023 May 26;25(1):87. doi: 10.1186/s13075-023-03071-1. Arthritis Res Ther. 2023. PMID: 37237413 Free PMC article.
-
Dopamine Receptor D3 Expression Is Altered in CD4+ T-Cells From Parkinson's Disease Patients and Its Pharmacologic Inhibition Attenuates the Motor Impairment in a Mouse Model.Front Immunol. 2019 May 1;10:981. doi: 10.3389/fimmu.2019.00981. eCollection 2019. Front Immunol. 2019. PMID: 31118938 Free PMC article.
-
The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.Curr Pharm Des. 2011;17(5):489-507. doi: 10.2174/138161211795164095. Curr Pharm Des. 2011. PMID: 21375482 Review.
-
alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach.CNS Neurol Disord Drug Targets. 2010 Aug;9(4):482-90. doi: 10.2174/187152710791556177. CNS Neurol Disord Drug Targets. 2010. PMID: 20522009 Review.
Cited by
-
Treating activated regulatory T cells with pramipexole protects human dopaminergic neurons from 6-OHDA-induced degeneration.CNS Neurosci Ther. 2024 Aug;30(8):e14883. doi: 10.1111/cns.14883. CNS Neurosci Ther. 2024. PMID: 39097919 Free PMC article.
-
Contributions of the Catechol-O-Methyltransferase Val158Met Polymorphism to Changes in Brain Iron Across Adulthood and Their Relationships to Working Memory.Front Hum Neurosci. 2022 Apr 27;16:838228. doi: 10.3389/fnhum.2022.838228. eCollection 2022. Front Hum Neurosci. 2022. PMID: 35571998 Free PMC article.
-
Chemokinergic and Dopaminergic Signalling Collaborates through the Heteromer Formed by CCR9 and Dopamine Receptor D5 Increasing the Migratory Speed of Effector CD4+ T-Cells to Infiltrate the Colonic Mucosa.Int J Mol Sci. 2024 Sep 18;25(18):10022. doi: 10.3390/ijms251810022. Int J Mol Sci. 2024. PMID: 39337509 Free PMC article.
-
A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered.Neuro Oncol. 2024 May 3;26(Supplement_2):S136-S154. doi: 10.1093/neuonc/noad144. Neuro Oncol. 2024. PMID: 37589388 Free PMC article. Review.
-
The immune system in Parkinson's disease: what we know so far.Brain. 2024 Oct 3;147(10):3306-3324. doi: 10.1093/brain/awae177. Brain. 2024. PMID: 38833182 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials